CD4 and rheumatoid arthritis: MTX significantly relieved arthritis activity and reduced the percentage of CD4+CD28−OX40+ T cells in PB samples of patients with RA (5.93 ± 1.80% vs 7.74 ± 2.54% posttherapy vs pretherapy, P = 0.038) after 16 weeks of treatment.